 |
|
|
| |
Integrated Analysis of Emergent Drug Resistance
from the HIV-1 Phase 3 QUAD Studies through Week 48
|
| |
| |
Reported by Jules Levin
International Workshop on HIV &
Hepatitis Virus Drug Resistance and Curative Strategies
June 5-9, 2012, Sitges, Spain
K White, R Kulkarni, J Szwarcberg, E Quirk, AK Cheng, and MD Miller
Gilead Sciences, Inc., California, USA
|
| |
|
|
|
|
|
